November 20, 2025
OXFORD, UK and CLEVELAND, Ohio, US, 20 November 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’) today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. Each Scholar will receive an advisory team providing...
Continue Reading
February 18, 2025
Renowned US Neuroscientist and Harvard Professor brings extensive expertise in academia and industry to advance rare disease research Continue Reading
February 05, 2025
Award highlights collaboration between for profit and non-profit achieving great impact Continue Reading
January 15, 2025
Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading
December 03, 2024
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival Continue Reading
November 15, 2024
Oxford, UK – 15th November 2024 – (or ‘the Company’, www.alveogene.com), a company focused on transforming rare respiratory disease outcomes using inhaled gene therapy, announces that it has been granted a Rare Pediatric Disease Designation (RPDD) by the US Food & Drug Administration (FDA) for AVG-002, its novel... Continue Reading
October 24, 2024
10 scientists have been selected for OHC’s first annual award to advance academic discoveries into clinical practice for rare diseases Continue Reading
October 15, 2024
Lord Cameron will lead international efforts to drive the OHC’s mission of delivering 40 new therapies for rare diseases into clinical trials over the next ten years Continue Reading
September 26, 2024
Grant award provides MD/PhD candidates with funding and expertise to translate promising scientific discoveries into medicines Continue Reading
September 24, 2024
The Symposium explores how cutting-edge research, innovative treatment strategies, and collaboration is driving the development of effective therapies for rare diseases. Continue Reading
September 11, 2024
In her position on OHC’s Advisory Council, Baroness Blackwood will contribute to advancing OHC’s mission to drive life-changing discoveries in rare disease, with a particular focus on addressing critical unmet needs in the UK. Continue Reading